PARP

Ongoing clinical trials and approved products targeting PARP, in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials
8ongoing imaging trials
0approved products

Target note

Full name
Poly(ADP-ribose) polymerase (PARP-1)
Nature
Nuclear DNA repair enzyme, target of PARP inhibitors.
Normal expression
Spleen, lymph nodes, liver.
Value
Measuring PARP expression and occupancy to predict the response to inhibitors.
Approaches
[18F]FTT (fluorthanatrace), [18F]PARPi.
Indications explored
Breast, ovarian and prostate cancers, gliomas.
Points of caution
Data still limited.

Ongoing imaging trials · 8Open in the radar →

TrialPhaseStatusSponsorCountries
[18F]FTT (PARP)NCT07723651 · Prostate – otherPhase 2Not yet recruitingWashington University School of Medicine1
[18F]FTT (PARP)NCT05226663 · BreastPhase 2Active, not recruitingM.D. Anderson Cancer Center1
[18F]FTT (PARP)NCT07673341 · Solid tumors (multiple indications)Phase 2RecruitingUniversity of Washington1
[18F]-olaparib · [18F]FTT (PARP)NCT06482307 · Head and neckPhase 2Not yet recruitingUniversity Medical Center Groningen1
[18F]FTT (PARP)NCT03631017 · Head and neckPhase 2Active, not recruitingMemorial Sloan Kettering Cancer Center1
[18F]FTT (PARP)NCT05636540 · Pheochromocytoma / paragangliomaPhase 1RecruitingHeather Wachtel1
[18F]FTT (PARP)NCT07114939 · Gastroenteropancreatic NETsPhase 1RecruitingAbramson Cancer Center at Penn Medicine1
[18F]FTT (PARP)NCT03083288 · BreastPhase 1Active, not recruitingAbramson Cancer Center at Penn Medicine1

Cite this page

PARP. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/parp/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.